Year
DEALS // DEV.
Country
Therapeutic Area
Study Phase
Deal Type
Product Type
Dosage Form
Lead Product
Target
GlyTherix Partners with SHINE Technologies For Radiotherapy in Aggressive Cancers
Details : Under the terms of agreement, SHINE will supply its n.c.a. Lu-177 chloride, Ilumira, for use in GlyTherix's clinical trials focused on innovative treatments for aggressive and invasive cancers.
Product Name : 177-Lu DOTA Miltuximab
Product Type : Antibody
Upfront Cash : Undisclosed
September 18, 2024